vs

Side-by-side financial comparison of AGNC Investment Corp. (AGNC) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

AGNC Investment Corp. is the larger business by last-quarter revenue ($206.0M vs $127.1M, roughly 1.6× Zai Lab Ltd). On growth, AGNC Investment Corp. posted the faster year-over-year revenue change (79.1% vs 17.1%). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs 7.9%).

The Russell 1000 Index is a U.S. stock market index that tracks the largest 1,000 stocks in the Russell 3000 Index, which represent about 93% of the total market capitalization of that index. The index is market cap weighted, meaning larger companies have a greater influence on the index than smaller companies.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

AGNC vs ZLAB — Head-to-Head

Bigger by revenue
AGNC
AGNC
1.6× larger
AGNC
$206.0M
$127.1M
ZLAB
Growing faster (revenue YoY)
AGNC
AGNC
+62.0% gap
AGNC
79.1%
17.1%
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
7.9%
AGNC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AGNC
AGNC
ZLAB
ZLAB
Revenue
$206.0M
$127.1M
Net Profit
$954.0M
Gross Margin
51.0%
Operating Margin
-54.6%
Net Margin
463.1%
Revenue YoY
79.1%
17.1%
Net Profit YoY
682.0%
EPS (diluted)
$0.90
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGNC
AGNC
ZLAB
ZLAB
Q4 25
$206.0M
$127.1M
Q3 25
$148.0M
$115.4M
Q2 25
$162.0M
$109.1M
Q1 25
$159.0M
$105.7M
Q4 24
$108.5M
Q3 24
$-64.0M
$101.8M
Q2 24
$-3.0M
$100.1M
Q1 24
$-30.0M
$87.1M
Net Profit
AGNC
AGNC
ZLAB
ZLAB
Q4 25
$954.0M
Q3 25
$806.0M
$-36.0M
Q2 25
$-140.0M
$-40.7M
Q1 25
$50.0M
$-48.4M
Q4 24
Q3 24
$346.0M
$-41.7M
Q2 24
$-48.0M
$-80.3M
Q1 24
$443.0M
$-53.5M
Gross Margin
AGNC
AGNC
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
AGNC
AGNC
ZLAB
ZLAB
Q4 25
-54.6%
Q3 25
-42.3%
Q2 25
-50.3%
Q1 25
-53.3%
Q4 24
-62.6%
Q3 24
-66.6%
Q2 24
-76.0%
Q1 24
-80.7%
Net Margin
AGNC
AGNC
ZLAB
ZLAB
Q4 25
463.1%
Q3 25
544.6%
-31.2%
Q2 25
-86.4%
-37.3%
Q1 25
31.4%
-45.8%
Q4 24
Q3 24
-540.6%
-40.9%
Q2 24
1600.0%
-80.2%
Q1 24
-1476.7%
-61.4%
EPS (diluted)
AGNC
AGNC
ZLAB
ZLAB
Q4 25
$0.90
$-0.05
Q3 25
$0.72
$-0.03
Q2 25
$-0.17
$-0.04
Q1 25
$0.02
$-0.04
Q4 24
$-0.09
Q3 24
$0.39
$-0.04
Q2 24
$-0.11
$-0.08
Q1 24
$0.59
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGNC
AGNC
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$450.0M
$689.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$12.4B
$715.5M
Total Assets
$115.1B
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGNC
AGNC
ZLAB
ZLAB
Q4 25
$450.0M
$689.6M
Q3 25
$450.0M
$717.2M
Q2 25
$656.0M
$732.2M
Q1 25
$455.0M
$757.3M
Q4 24
$779.7M
Q3 24
$507.0M
$616.1M
Q2 24
$530.0M
$630.0M
Q1 24
$505.0M
$650.8M
Stockholders' Equity
AGNC
AGNC
ZLAB
ZLAB
Q4 25
$12.4B
$715.5M
Q3 25
$11.4B
$759.9M
Q2 25
$10.3B
$791.7M
Q1 25
$10.0B
$810.8M
Q4 24
$840.9M
Q3 24
$9.7B
$667.7M
Q2 24
$8.7B
$704.2M
Q1 24
$8.6B
$762.2M
Total Assets
AGNC
AGNC
ZLAB
ZLAB
Q4 25
$115.1B
$1.2B
Q3 25
$109.0B
$1.2B
Q2 25
$102.0B
$1.2B
Q1 25
$95.9B
$1.2B
Q4 24
$1.2B
Q3 24
$89.6B
$985.3M
Q2 24
$79.7B
$987.4M
Q1 24
$71.9B
$988.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGNC
AGNC
ZLAB
ZLAB
Operating Cash FlowLast quarter
$653.0M
$-26.0M
Free Cash FlowOCF − Capex
$-26.7M
FCF MarginFCF / Revenue
-21.0%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
0.68×
TTM Free Cash FlowTrailing 4 quarters
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGNC
AGNC
ZLAB
ZLAB
Q4 25
$653.0M
$-26.0M
Q3 25
$153.0M
$-32.0M
Q2 25
$180.0M
$-31.0M
Q1 25
$192.0M
$-61.7M
Q4 24
$-55.8M
Q3 24
$7.0M
$-26.8M
Q2 24
$-20.0M
$-42.2M
Q1 24
$20.0M
$-90.1M
Free Cash Flow
AGNC
AGNC
ZLAB
ZLAB
Q4 25
$-26.7M
Q3 25
$-35.0M
Q2 25
$-33.9M
Q1 25
$-63.2M
Q4 24
$-58.4M
Q3 24
$-28.2M
Q2 24
$-42.9M
Q1 24
$-91.1M
FCF Margin
AGNC
AGNC
ZLAB
ZLAB
Q4 25
-21.0%
Q3 25
-30.4%
Q2 25
-31.1%
Q1 25
-59.9%
Q4 24
-53.8%
Q3 24
-27.7%
Q2 24
-42.9%
Q1 24
-104.5%
Capex Intensity
AGNC
AGNC
ZLAB
ZLAB
Q4 25
0.5%
Q3 25
2.6%
Q2 25
2.6%
Q1 25
1.5%
Q4 24
2.4%
Q3 24
1.3%
Q2 24
0.7%
Q1 24
1.1%
Cash Conversion
AGNC
AGNC
ZLAB
ZLAB
Q4 25
0.68×
Q3 25
0.19×
Q2 25
Q1 25
3.84×
Q4 24
Q3 24
0.02×
Q2 24
Q1 24
0.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AGNC
AGNC

Segment breakdown not available.

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons